2026 MaTOS GU | Session VII | Metastatic Renal Cell Cancer (RCC)
Overview
Dr. Zakaria reviewed HIF2α inhibitors in RCC: belzutifan shows strong ORR/PFS; combos improve outcomes; promising roles in frontline and adjuvant settings.
Dr. Voss reviewed non-clear cell RCC: diverse biology needs tailored therapy; cabozantinib/ICIs help papillary, less in chromophobe; new targets under study.
Dr. Chahoud: STELLAR-0O2 trial—Zanza+nivo showed strong ORR (63%) and PFS (18.5 mo); triplet underperformed; supports further IO combo development.
Dr. Tawagi: irAEs common with IO (higher in combos); onset 4–12 wks; manage with monitoring, steroids, and targeted agents like infliximab.
The panel discussed on non-clear RCC: NGS testing useful; nephritis management complex; single-arm trials preferred; belzutifan and new targets (NPP3, CA9) under study.
Dr. Voss reviewed non-clear cell RCC: diverse biology needs tailored therapy; cabozantinib/ICIs help papillary, less in chromophobe; new targets under study.
Dr. Chahoud: STELLAR-0O2 trial—Zanza+nivo showed strong ORR (63%) and PFS (18.5 mo); triplet underperformed; supports further IO combo development.
Dr. Tawagi: irAEs common with IO (higher in combos); onset 4–12 wks; manage with monitoring, steroids, and targeted agents like infliximab.
The panel discussed on non-clear RCC: NGS testing useful; nephritis management complex; single-arm trials preferred; belzutifan and new targets (NPP3, CA9) under study.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Jad Chahoud, MD, MPH-MHA
Arpita Desai, MD
Karine Tawagi, MD
MarYn H. Voss, MD
Yousef Zakharia, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
